Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

A Positive Outlook For Deals, With Election Year Caveats

Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year.

Topic biopharmaceutical

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

Regular Acceptance Of Simulation Studies More Likely In 2020s

Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.

Topic biopharmaceutical

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Scrip Preview Pharma Trends for 2020

For Scrip’s annual preview, our journalists asked over 80 industry executives and experts for their predictions of the major trends for 2020. From AI to M&A, gene therapy to the upcoming US election, here’s what to watch for as we begin this  new decade.

Topic biosimilars biopharmaceutical

Trialtrove: 医療用医薬品の臨床試験情報データベース

Trialtrove 2018 Clinical Trials Roundup Surveying the Landscape of 2018 Trial Starts infographic

A clear view of the past is often the surest way to plan for the future. The annual analysis of Phase I-III clinical trials from Citeline’s Trialtrove reveals the priorities and strategies of the biopharma industry. This infographic lets you clearly see the players, trials, and trends.  

Topic drug-development-landscape biopharmaceutical business-strategies

Trialtrove: 医療用医薬品の臨床試験情報データベース

2018年に開始された臨床試験を総括・無料ホワイトペーパー

2018年に開始された第I相臨床試験～第III相臨床試験を総括する無料ホワイトペーパー「2018 Clinical Trials Roundup: Surveying the Landscape of 2018 Trial Starts(全22頁)」をダウンロードできます。2018年に開始された臨床試験とその競合状況を鳥の目で分析して、バイオ医薬品産業全体のトレンドを明らかにしています。また、個々の企業の戦略や優先課題も考察しています。

Topic drug-development-landscape biopharmaceutical business-strategies

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Woodford Debacle Is A Test Of UK Biotech's Resilience

Investor's Downfall is Unwelcome Distraction: As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.

Topic BioPharmaceutical Company analysis

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research

Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting.

Topic research biopharmaceutical

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

At Pfizer, A Split A Decade In The Making

Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.

Topic biopharmaceutical company-analysis